{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:16:17Z","timestamp":1786119377860,"version":"build-2736575974"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1097\/aci.0b013e328357d3ba","type":"journal-article","created":{"date-parts":[[2012,8,21]],"date-time":"2012-08-21T10:18:18Z","timestamp":1345544298000},"page":"510-516","source":"Crossref","is-referenced-by-count":33,"title":["Ophthalmic antihistamines and H1\u2013H4 receptors"],"prefix":"10.1097","volume":"12","author":[{"given":"Laurie","family":"Wade","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard","family":"Bielory","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shara","family":"Rudner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1358\/dot.2011.47.12.1709243","article-title":"Alcaftadine: a topical antihistamine for use in allergic conjunctivitis.","volume":"47","author":"Namdar","year":"2011","journal-title":"Drugs Today"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1097\/01.all.0000183113.63311.11","article-title":"Histamine receptors and the conjunctiva.","volume":"5","author":"Bielory","year":"2005","journal-title":"Curr Opin Allergy Clin Immunol"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2165\/00003495-200565020-00004","article-title":"Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis.","volume":"65","author":"Bielory","year":"2005","journal-title":"Drugs"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd2465","article-title":"The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines.","volume":"7","author":"Thurmond","year":"2008","journal-title":"Nat Rev Drug Discovery"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1001\/archopht.1981.03930010304018","article-title":"H2-receptors in the human ocular surface.","volume":"99","author":"Abelson","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrd1631","article-title":"The histamine H3 receptor: from gene cloning to H3 receptor drugs.","volume":"4","author":"Leurs","year":"2005","journal-title":"Drug Discovery"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"391","DOI":"10.2500\/105065899781367483","article-title":"Combined histamine H1 and H3 receptor blockade produces nasal decongestion in an experimental model of nasal congestion.","volume":"13","author":"McLeod","year":"1999","journal-title":"Am J Rhinol"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jaci.2011.11.026","article-title":"The effects of an H3 receptor antagonist (PF-03654746) with fexofenadine on reducing allergic rhinitis symptoms.","volume":"129","author":"Stokes","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"R9-13-20210128","first-page":"5","article-title":"Histamine H4 antagonism: a therapy for chronic allergy Br J P","volume":"142","author":"Daugherty","year":"2004","journal-title":"harmacol"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1124\/jpet.105.087965","article-title":"Evaluation of Histamine H1-, H2-, and H3-Receptor Ligands at the Human Histamine H4 Receptor: identification of 4-Methylhistamine as the First Potent and Selective H4 Receptor Agonist.","volume":"314","author":"Lim","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"7062","DOI":"10.4049\/jimmunol.176.11.7062","article-title":"The Histamine H4 receptor mediates allergic airway inflammation by regulating the activation of CD4 T Cells.","volume":"176","author":"Dunford","year":"2006","journal-title":"J Immunol"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jaci.2006.08.034","article-title":"Histamine H4 receptor antagonists are superior to traditional antihistamines in the attenuation of experimental pruritis.","volume":"119","author":"Dunford","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1016\/S0022-3565(25)20776-5","article-title":"Characterization of the ocular ant allergic and antihistaminic effects of olopatadine (AL-4943A0) a novel drug for treating ocular allergic diseases.","volume":"278","author":"Sharif","year":"1996","journal-title":"J Pharmacol Exp Ther"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1089\/jop.1994.10.653","article-title":"Emedastine: a potent, high affinity histamine H1-receptor-selective antagonist for ocular use: receptor binding and second messenger studies.","volume":"10","author":"Sharif","year":"1994","journal-title":"J Ocular Pharmacol"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/S0002-9394(03)00708-6","article-title":"Efficacy and safety of ketotifen fumarate 0.025 in the conjunctival antigen challenge model of ocular allergic conjunctivitis.","volume":"136","author":"Greiner","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/S0149-2918(02)85042-1","article-title":"Randomized, double-masked, placebo-controlled comparison of the efficacy of emedastine difumarate 0.05 ophthalmic solution and ketotifen fumarate 0.025 ophthalmic solution in the human conjunctival allergen challenge model.","volume":"24","author":"DArienzo","year":"2002","journal-title":"Clin Ther"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1016\/S0149-2918(00)83044-1","article-title":"Comparison of the clinical efficacy and comfort of olopatadine hydrochloride 0.1 ophthalmic solution and nedocromil sodium 2 ophthalmic solution in the human conjunctival allergen challenge model.","volume":"22","author":"Butrus","year":"2000","journal-title":"Clin Ther"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1016\/S0149-2918(00)80055-7","article-title":"A comparison of the relative efficacy and clinical performance of olopatadine hydrochloride 0.1 ophthalmic solution in the conjunctival antigen challenge model.","volume":"22","author":"Berdy","year":"2000","journal-title":"Clin Ther"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1016\/0014-2999(83)90311-4","article-title":"Inhibition of calcium ionophore (A23187)-stimulated histamine release from rat peritoneal mast cells by Asselstine: implications for its mode of action.","volume":"96","author":"Chand","year":"1985","journal-title":"Eur J Pharmacol"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2500\/aap.2012.33.3525","article-title":"Allergic conjunctivitis: The evolution of therapeutic options.","volume":"33","author":"Bielory","year":"2012","journal-title":"Allergy Asthma Proc"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0149-2918(04)90004-5","article-title":"Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis.","volume":"26","author":"Abelson","year":"2004","journal-title":"Clin Ther"},{"key":"R23-13-20210128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1089\/jop.2011.0005","article-title":"Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.","volume":"27","author":"Williams","year":"2011","journal-title":"J Ocul Pharmacol Ther"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.ajo.2010.02.007","article-title":"Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0 and 1.5 to treat allergic conjunctivitis.","volume":"150","author":"Macejko","year":"2010","journal-title":"Am J Ophthalmol"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.exer.2010.04.006","article-title":"Bepotastine besilate, a highly selective histamine H1 receptor antagonist, suppresses vascular hyperpermeability and eosinophil recruitment in in vitro and in vivo experimental allergic conjunctivitis models.","volume":"91","author":"Kida","year":"2010","journal-title":"Exp Eye Res"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1089\/jop.2010.0153","article-title":"Clinical pharmacology of alcaftadine, a novel antihistamine for the prevention of allergic conjunctivitis.","volume":"27","author":"Bohets","year":"2011","journal-title":"J Ocul Pharmacol Th"},{"key":"R27-13-20210128","first-page":"77","article-title":"Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis.","volume":"5","author":"Ono","year":"2011","journal-title":"Drug Des Develop Ther"},{"key":"R28-13-20210128","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1185\/03007995.2010.548797","article-title":"The safety and efficacy of alcaftadine 0.25 ophthalmic solution for the prevention of itching associated with allergic conjunctivitis.","volume":"27","author":"Torkildsen","year":"2011","journal-title":"Curr Med Res Opin"},{"key":"R29-13-20210128","first-page":"87","article-title":"Evaluation of alcaftadine 0.25 ophthalmic solution in acute allergic conjunctivitis at 15 min and 16h after instillation versus placebo and olopatadine 0.1.","volume":"5","author":"Greiner","year":"2011","journal-title":"Clin Ophthalmol"}],"container-title":["Current Opinion in Allergy & Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/ACI.0b013e328357d3ba","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:23:55Z","timestamp":1786040635000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00130832-201210000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":28,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/aci.0b013e328357d3ba","relation":{},"ISSN":["1528-4050"],"issn-type":[{"value":"1528-4050","type":"print"}],"subject":[],"published":{"date-parts":[[2012,10]]}}}